Mitchell Capital Management Co. decreased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 12.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,583 shares of the biotechnology company’s stock after selling 8,164 shares during the period. Mitchell Capital Management Co. owned 0.05% of Corcept Therapeutics worth $3,939,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its position in Corcept Therapeutics by 2.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,136,510 shares of the biotechnology company’s stock valued at $243,708,000 after purchasing an additional 57,942 shares during the last quarter. Invesco Ltd. boosted its position in Corcept Therapeutics by 76.5% during the first quarter. Invesco Ltd. now owns 1,246,234 shares of the biotechnology company’s stock valued at $142,345,000 after purchasing an additional 540,101 shares during the last quarter. Northern Trust Corp boosted its position in Corcept Therapeutics by 0.6% during the first quarter. Northern Trust Corp now owns 1,022,001 shares of the biotechnology company’s stock valued at $116,733,000 after purchasing an additional 6,486 shares during the last quarter. Cerity Partners LLC boosted its position in Corcept Therapeutics by 1.1% during the first quarter. Cerity Partners LLC now owns 614,794 shares of the biotechnology company’s stock valued at $70,222,000 after purchasing an additional 6,848 shares during the last quarter. Finally, Jupiter Asset Management Ltd. boosted its position in Corcept Therapeutics by 8,176.0% during the first quarter. Jupiter Asset Management Ltd. now owns 603,903 shares of the biotechnology company’s stock valued at $68,978,000 after purchasing an additional 596,606 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.
Corcept Therapeutics Price Performance
NASDAQ CORT opened at $73.96 on Monday. The firm has a market cap of $7.79 billion, a PE ratio of 65.45 and a beta of 0.46. Corcept Therapeutics Incorporated has a one year low of $42.01 and a one year high of $117.33. The stock’s 50 day simple moving average is $75.57 and its 200 day simple moving average is $73.31.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on CORT shares. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Wednesday, October 8th. Piper Sandler reduced their price target on Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating for the company in a research report on Friday, August 1st. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, September 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $145.00 price target on shares of Corcept Therapeutics in a research report on Friday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and an average target price of $135.25.
View Our Latest Analysis on Corcept Therapeutics
Insiders Place Their Bets
In other news, CEO Joseph K. Belanoff sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $85.08, for a total value of $3,403,200.00. Following the completion of the transaction, the chief executive officer owned 2,781,370 shares in the company, valued at $236,638,959.60. This trade represents a 1.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $72.45, for a total value of $159,390.00. The disclosure for this sale can be found here. Insiders have sold 304,610 shares of company stock worth $22,713,516 over the last 90 days. 20.80% of the stock is currently owned by corporate insiders.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
See Also
- Five stocks we like better than Corcept Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Microsoft 365 Premium Marks the Next Phase of AI Monetization
- Insider Trades May Not Tell You What You Think
- Could Target’s Week of Discounts Come Full Circle for Investors?
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.